OTCMKTS:AXIM AXIM Biotechnologies (AXIM) Stock Price, News & Analysis $0.0034 0.00 (0.00%) As of 12:40 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About AXIM Biotechnologies Stock (OTCMKTS:AXIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AXIM Biotechnologies alerts:Sign Up Key Stats Today's Range$0.0034▼$0.003450-Day Range N/A52-Week Range$0.00▼$0.03Volume400,500 shsAverage Volume276,183 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AXIM Biotechnologies, Inc. is a biotechnology company focused on developing diagnostic technologies and related healthcare products. Its activities have included research into rapid immunoassay platforms designed to detect biological markers in areas such as infectious disease and oral health. During the COVID-19 pandemic, AXIM worked on diagnostic products intended to identify SARS-CoV-2 infection and neutralizing antibodies. The company has also explored applications for its testing technologies in oral-care and other clinical settings, although product availability and regulatory status may vary by product and jurisdiction. AXIM’s business has primarily centered on research, product development, and potential commercialization through regulatory and strategic partnerships. Publicly available information about its current commercial operations, geographic reach, and leadership is limited, and the company’s focus may evolve as its development programs progress.AI Generated. May Contain Errors. Read More Receive AXIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AXIM Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXIM Stock News HeadlinesAXIM Biotechnologies Submits 510(k) to FDA for Next-Generation, Rapid Point-of-Care Tear Lactoferrin Test for Dry Eye DiseaseOctober 6, 2026 | theglobeandmail.comAxim Biotechnologies Inc.April 16, 2026 | barrons.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs AdvisorJanuary 20, 2026 | finance.yahoo.comAXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South KoreaOctober 23, 2025 | finance.yahoo.comAXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic TestsOctober 7, 2025 | finance.yahoo.comAxim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic TestJune 24, 2025 | finance.yahoo.comAXIM Biotechnologies, Inc. (AXIM) Latest Stock News & Headlines - Yahoo FinanceApril 25, 2025 | finance.yahoo.comSee More Headlines AXIM Stock Analysis - Frequently Asked Questions How have AXIM shares performed this year? AXIM Biotechnologies' stock was trading at $0.0107 at the beginning of the year. Since then, AXIM shares have decreased by 68.2% and is now trading at $0.0034. How do I buy shares of AXIM Biotechnologies? Shares of AXIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AXIM Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that AXIM Biotechnologies investors own include Cronos Group (CRON), Tilray Brands (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), Organigram Global (OGI), Charlotte's Web (CWBHF) and Medical Marijuana (MJNA). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:AXIM CIK1514946 Webaximbiotech.com Phone(858) 923-4422FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:AXIM) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AXIM Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AXIM Biotechnologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
